Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum COSCIENS Biopharma Inc T.CSCI

Alternate Symbol(s):  CSCI

Healthcare Biotechnology
COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone... see more

Bullboard (TSX:CSCI)

View:
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Comment by prophetoffactzon Aug 11, 2024 2:21pm

RE:Avenanthramide pill

The Lancet Publishes Results from World's Largest Coronary CT Registry Showing New AI Technology Can Predict Cardiac Events Due to Coronary Inflammation At Least 10 Years in Advance    ...more  
30
Discussion
Post by prophetoffactzon Aug 11, 2024 2:04pm

Avenanthramide pill

Avenanthramide was the reason Gilles wanted to join CZO originally. More recently, in a December 2022 news release Gilles stated: "...our avenanthramide program and could be the most significant ...more  
140
Discussion
Post by prophetoffactzon Aug 11, 2024 12:19pm

New Diagnostic Licensing Deal:

In July 2023, in a news release, AEZS said "...based upon our active outreach and discussions, we expect to secure an alternate development and commercialization partner for Macrilen®  ...more  
119
Comment by prophetoffactzon Aug 11, 2024 11:23am

RE:PGX Scale-up:

What percentage of the yeast beta glucan immune booster market could CSCI take with a potentially clearly superior source of yeast beta glucan further enhanced by PGX? CSCI and partner could have a ...more  
38
Discussion
Post by prophetoffactzon Aug 11, 2024 10:52am

PGX Scale-up:

Tomorrow will be 15 weeks since the scale-up of PGX to 50L was said "almost completed" after three trial runs. Three trial runs would allow a judgement concerning the repeatability of ...more  
107
Discussion
Post by Hopeforthebeston Aug 09, 2024 11:42am

RE: PGX-YBG

proph said "Based on the average timeline from submission to the journal Biomaterials to publishing the comprehensive article on PGX-YBG/Fibrosis could be published within the next 30 days"  ...more  
91
Post by prophetoffactzon Aug 09, 2024 9:14am

PGX-YBG

Based on the average timeline from submission to the journal Biomaterials to publishing the comprehensive article on PGX-YBG/Fibrosis could be published within the next 30 days. In the October Small ...more  
61
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities